Martin Shkreli gained a number of monikers in his rise to infamy. Pharma Bro. Most hated man in America. Face of corporate greed.
Executives in the drug industry call him something else: catalyst.
"He was, in the great scheme of things, a drop in the bucket," said Ron Cohen, CEO of biotech company Acorda Therapeutics and past chair of the Biotechnology Innovation Organization industry group. "But he created such a massive impression and blowback that it forced entire industries, government, patient advocacy groups, the media and political entities all to focus on these issues in a way that I don't know that they would have absent that event."
The nearly three-year saga that saw Shkreli come to prominence as a pharmaceutical CEO, raise the price of a 60-year-old medicine by 5,000 percent, purchase a single-copy Wu-Tang Clan album for $2 million, get arrested on unrelated charges of securities fraud, troll America, get convicted, and be sent to prison in a bizarre set of circumstances involving Hillary Clinton's hair follicles ostensibly came to an end Friday, when he was sentenced by a federal judge to seven years in prison.